Japan Daily Briefing

Japanese banks and financials added +0.80% on the session, consistent with the value-rotation thesis that underpins the Buffett-Japan trading houses and TSE governance reform story. Banks benefit from BoJ normalization: every 10bps hike in the overnight rate adds materially to NIM for Mitsubishi UFJ, Sumitomo Mitsui, and Mizuho. The sector's resilience today despite broad market uncertainty is notable — it confirms that institutional money is still allocating to PBR-recovery names as the TSE reform mandate on capital efficiency extends into Q2 FY27 earnings season.

Japan pharma's +2.50% gain was the session's standout — the best sectoral performance by a wide margin — signalling a defensive rotation bid as investors de-risk ahead of the weekend. Japan pharma names like Daiichi Sankyo (partner on AstraZeneca's Enhertu ADC franchise) benefit from both the yen tailwind on dollar-denominated licensing revenue AND the defensive rotation into healthcare when equity uncertainty rises. AstraZeneca's Q2 earnings preview (reporting July 27 with EPS consensus at $1.27) puts Daiichi Sankyo's royalty stream directly in focus — a strong AZN print would catalyse another leg up in Japan pharma next week.

Financial Post reported that a growing number of global banks are advising traders to position for a hawkish BoJ response to the yen's four-decade low. This is the single biggest macro risk overhanging Japan equities: if BoJ raises rates, JPY strengthens, exporter earnings face translation headwind, and — critically — the carry trade unwind hits global bond markets. The WisdomTree Japan Hedged ETF's +0.86% vs. iShares MSCI Japan +0.12% spread today quantifies exactly what a 10% yen recovery would cost unhedged Japan holders: roughly a 3-4% NAV gap in a single week.